Gilead Sciences said Wednesday that remdesivir, which has been authorized for emergency use since the spring, brought in $873 million in revenues so far this year, even though no studies have shown that it lowers death rates
A sign is posted in front of the Gilead Sciences headquarters on April 29, 2020 in Foster City, California. Gilead Sciences announced preliminary results of a drug trial with that showed at least 50% of patients with coronavirus that treated with a five-day dosage of remdesivir improved and more than half were released from the hospital within two weeks. Image: Justin Sullivan/Getty Images
©2019 New York Times News Service